newsfilter
← Latest News
GlobeNewswire·

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre", "Gyre Therapeutics" or the "Company") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United